ERBB2 and inflammatory breast carcinoma: Significantly, it has been recently demonstrated that a loss of anti-HER-2 CD4+ Th1 responses in peripheral blood occurs during breast tumorigenesis which can be restored with HER-2 vaccinations in both DCIS and IBC [49].